CSTL · XBRL financial data

Castle Biosciences financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CSTL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	62,649	94,085	137,039	219,788	332,069	344,229
Cost of revenue	—	15,822	32,009	44,982	60,205	71,028
Cost of goods and services sold	9,685	15,822	—	—	—	—
Gross profit	52,964	—	—	—	—	—
Research and development	13,256	29,646	44,903	53,618	52,041	51,850
Selling, general and administrative	48,132	86,738	143,003	180,152	200,047	229,323
Other operating income (expense)	1,882	0	—	—	—	—
Operating income (loss)	(6,542)	(40,079)	(72,855)	(67,977)	8,670	(42,810)
Interest income	373	68	3,968	10,623	12,916	11,772
Interest expense	2,634	1	17	11	577	86
Other income (expense)	0	—	—	0	0	144
Income tax expense (benefit)	84	(8,720)	(1,766)	101	3,319	(5,356)
Net income (loss)	(10,284)	(31,292)	(67,138)	(57,466)	18,245	(24,158)
Earnings per share, basic USD per share	(0.54)	(1.24)	(2.58)	(2.14)	0.66	(0.83)
Earnings per share, diluted USD per share	(0.54)	(1.24)	(2.58)	(2.14)	0.62	(0.83)
Weighted average shares, basic thousands of shares	18,929	25,137	26,054	26,802	27,776	28,986
Weighted average shares, diluted thousands of shares	18,929	25,137	26,054	26,802	29,255	28,986

Fiscal years (CSTL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	409,852	329,633	122,948	98,841	119,709	116,729
Marketable securities	—	0	135,677	144,258	173,421	182,776
Marketable securities, non-current	—	—	—	—	0	—
Accounts receivable	12,759	17,282	23,476	38,302	51,218	43,382
Inventory	2,217	2,021	3,980	7,942	8,135	10,254
Prepaid and other current assets	4,766	4,807	6,207	6,292	7,671	7,956
Total current assets	429,594	353,743	292,288	295,635	360,154	361,097
Property and equipment, net	7,102	9,501	14,315	—	—	—
Right-of-use asset	0	7,383	12,181	12,306	11,584	14,795
Goodwill	—	0	10,692	10,700	10,700	10,700
Total assets	439,328	462,572	447,329	453,340	531,235	578,556
Accounts payable	2,098	2,546	4,731	10,268	6,901	18,711
Current portion of long-term debt	0	—	—	0	278	417
Total current liabilities	20,876	24,886	36,128	47,667	49,392	68,677
Long-term debt	0	—	—	0	9,745	9,640
Lease liability, non-current	0	6,900	11,533	14,173	14,345	25,217
Total liabilities	23,637	50,832	48,179	62,071	75,400	107,683
Accumulated deficit	(62,496)	(93,767)	(160,905)	(218,371)	(200,126)	(224,284)
Total stockholders' equity	415,691	411,740	399,150	391,269	455,835	470,873
Total liabilities and equity	439,328	462,572	447,329	453,340	531,235	578,556
Common shares outstanding (cover page) thousands of shares	24,978	25,411	26,576	27,450	28,514	29,731

Fiscal years (CSTL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(10,284)	(31,292)	(67,138)	(57,466)	18,245	(24,158)
Stock-based compensation	8,309	21,740	36,321	51,219	50,320	45,893
Depreciation and amortization	472	3,407	10,543	12,330	15,997	40,771
Net cash from operating activities	9,865	(18,983)	(41,655)	(5,626)	64,866	64,347
Purchases of property and equipment	4,751	3,483	5,632	13,621	28,326	36,021
Net cash from investing activities	(4,748)	(66,657)	(166,545)	(16,183)	(50,137)	(60,367)
Proceeds from issuing common stock	330,041	0	—	—	—	—
Net cash from financing activities	305,890	5,421	1,515	(2,298)	6,139	(6,960)
Net change in cash	311,007	(80,219)	(206,685)	(24,107)	20,868	(2,980)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Castle Biosciences	62,116	103,546	15,201*	30.5M	—	Q2 FY26 10-QJun 30, 2026
Personalis	98,271	25,596	(27,072)*	108.4M	6.7 quarters	Q3 FY26 10-QSep 30, 2026
BillionToOne	561,512	122,981	not reported	not reported	—	Q3 FY26 10-QSep 30, 2026
Celcuity	182,049	not reported	(55,426)*	48.9M	13.6 quarters	Q2 FY26 10-QJun 30, 2026
Fortrea Holdings	220,600	691,500	60,800*	96.5M	—	Q3 FY26 10-QSep 30, 2026
CareDx	250,480	139,362	12,718*	52.5M	—	Q3 FY26 10-QSep 30, 2026
Fulgent Genetics	26,305	85,389	(23,758)*	27.5M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Lumexa Imaging Holdings	69,705	264,162	32,801*	96.1M	—	Q2 FY26 10-QJun 30, 2026
Veracyte	299,521	150,321	45,826*	80.4M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.